New shot for obesity and diabetes passes first safety test
NCT ID NCT05925920
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested a single injection of a new drug called ENT-03S in 49 people who were either obese but otherwise healthy, or had both obesity and type 2 diabetes. The main goal was to check safety and how the drug moves through the body. Participants were randomly assigned to receive either the drug or a placebo, and were monitored for two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ENT-03S
- What this could lead to
- If successful, this could point toward a new injectable treatment for obesity and type 2 diabetes.
- What could go wrong
- This is a very early Phase 1 trial with only 49 people, focused on safety and dosing. It is too small to prove effectiveness, and many early-stage drugs do not advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ProSciento
San Diego, California, 91911, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?